Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was first developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include pexidartinibum and Turalio. Its PubChem CID is 25151352.
Pexidartinib
| CAS No | 1029044-16-3 |
|---|---|
| Molecular Formula | C20H15ClF3N5 |
| Molecular Weight | 417.8 g/mol |
| Synonyms | 5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]pyridin-2-amine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was first developed by Daiichi Sankyo, Inc.
The listed CAS number is 1029044-16-3.
The listed molecular formula is C20H15ClF3N5.
The listed molecular weight is 417.8 g/mol.
5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]pyridin-2-amine.
The source lists pexidartinibum and Turalio.